Compare Novartis AG (NVS) vs Vanguard Emerging Markets Stock Index Fund ETF (VWO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Vanguard Emerging Markets Stock Index Fund ETF — how do they compare? Novartis AG trades at $154.71 (market cap $295.37B), while Vanguard Emerging Markets Stock Index Fund ETF trades at $60.4. The key difference: Novartis AG pays a 3.07% dividend while Vanguard Emerging Markets Stock Index Fund ETF pays none, and Vanguard Emerging Markets Stock Index Fund ETF is trading nearer its 52-week high, Novartis AG nearer its low. Which is the better fit depends on your goals.
| NVS | VWO | |
|---|---|---|
Market Cap | $295.37B | — |
Sector | Health | — |
52-Week High | $168.62 | $61.24 |
52-Week Low | $119.31 | $51.20 |
Enterprise Value | $336.69B | — |
Dividend Yield | 3.07% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $152.41, down 2.79% today, with technical indicators showing neutral momentum near key support at $152. The company reported strong Q2 2026 earnings that beat expectations, driven by oncology drug performance, while maintaining a robust 22.5% net margin and $56.7B in revenue. Recent institutional buying activity and a predominantly Hold analyst consensus reflect cautious optimism amid patent expiration headwinds.
The outlook balances strong fundamentals and pipeline progress against generic competition risks. Investment appeal lies in dividend stability and new drug growth, though Entresto sales decline and U.S. pricing pressures require monitoring. The stock presents a defensive opportunity with moderate upside potential if newer therapies continue outperforming.
VWO, the Vanguard FTSE Emerging Markets ETF, trades at $60.41, up 0.13% on the day, with a bullish technical signal from moving averages and a neutral reading from oscillators. The fund's low expense ratio of 0.06% and focus on emerging markets attract institutional inflows, as seen in recent 13F filings. Recent news highlights strong capital flows into emerging market ETFs and comparisons with peers on cost and diversification.
The outlook for VWO is supported by record inflows and favorable expense ratios, but risks include concentrated exposure to developing economies and currency volatility. Analyst sentiment is generally positive due to diversification benefits and cost efficiency, though geopolitical and economic uncertainties in emerging markets pose significant headwinds for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Vanguard Emerging Markets Stock Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Emerging Markets All Cap China A Inclusion Index. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the index in terms of key characteristics.
Read more on VWO →
